Exploratory Study of Breast Cancer With ABY025

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biomedical Radiation Sciences
• Collaborator: Swedish Cancer Society

Criteria

Inclusion Criteria:

• female age >20 years

• one or more known metastases localizations

Exclusion Criteria:

• other critical disease than breast cancer

• age ≤ 20 years